{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:01:27Z","timestamp":1777420887473,"version":"3.51.4"},"reference-count":172,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>Objectives: To discuss (1) recent and emerging data for pharmacological management of untreated and relapsed\/refractory (R\/R) mantle cell lymphoma (MCL) with agents approved in the United States, (2) important considerations for toxicity monitoring and management, and (3) preliminary data and ongoing studies for agents in MCL-specific clinical trials. Data Sources: PubMed\/MEDLINE, EMBASE, Google Scholar, product labeling, National Comprehensive Cancer Network, American Cancer Society, and ClinicalTrials.gov were searched for studies published between January 1, 2017, and January 31, 2020, and key historical trials. Study Selection and Data Extraction: Relevant studies conducted in humans and selected supporting preclinical data were reviewed. Data Synthesis: MCL is a rare but usually aggressive non-Hodgkin lymphoma that most commonly affects the older population. Traditionally, the treatment of MCL has been determined based on transplant eligibility. Newer data suggest that more tolerable frontline therapy may produce outcomes similar to intensive historical induction regimens, possibly precluding fewer patients from autologous stem cell transplant and producing better long-term outcomes in transplant-ineligible patients. In the R\/R setting, novel regimens are improving outcomes and changing the landscape of treatment. Relevance to Patient Care and Clinical Practice: This review summarizes and discusses recent and emerging data for management of newly diagnosed and R\/R MCL; key supportive care considerations for agents are also discussed. Conclusions: Recent study results are changing management of MCL. Although these data have complicated the picture of regimen selection, increasingly effective and tolerable therapy and additional anticipated data point to a brighter future for patients with MCL.<\/jats:p>","DOI":"10.1177\/1060028020909117","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T01:26:31Z","timestamp":1582248391000},"page":"879-898","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents"],"prefix":"10.1177","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9063-1495","authenticated-orcid":false,"given":"Michael J.","family":"Buege","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Kumar","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brianne N.","family":"Dixon","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura A.","family":"Tang","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Pak","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Orozco","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5095-859X","authenticated-orcid":false,"given":"Tim J.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn T.","family":"Maples","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"bibr1-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"bibr2-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23608"},{"key":"bibr3-1060028020909117","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22367"},{"key":"bibr4-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.8.2726.2726"},{"key":"bibr5-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-862151"},{"key":"bibr6-1060028020909117","unstructured":"AstraZeneca. CALQUENCE. NCCNetwork guidelines: B-cell lymphomas (version 4.2018). https:\/\/www.calquencehcp.com\/physician\/about-mcl-treatment\/nccn-guidelines.html. Published May 15, 2018. Accessed September 2018."},{"key":"bibr7-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.8435"},{"key":"bibr8-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0209-5"},{"key":"bibr9-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3803"},{"key":"bibr10-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"bibr11-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt070"},{"key":"bibr12-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08958.x"},{"key":"bibr13-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13796"},{"key":"bibr14-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14480"},{"key":"bibr15-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.04.011"},{"key":"bibr16-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2003.00093.x"},{"key":"bibr17-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-147025"},{"key":"bibr18-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11838"},{"key":"bibr19-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14241"},{"key":"bibr20-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00739-X"},{"key":"bibr21-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk152"},{"key":"bibr22-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701769"},{"key":"bibr23-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01294"},{"key":"bibr24-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1508672"},{"key":"bibr25-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25362"},{"key":"bibr26-1060028020909117","volume":"130","author":"Le Gouill S","year":"2017","journal-title":"Blood"},{"key":"bibr27-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1002\/hon.13_2629"},{"key":"bibr28-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1571205"},{"key":"bibr29-1060028020909117","unstructured":"Memorial Sloan Kettering Cancer Center. Sequential chemotherapy and lenalidomide followed by rituximab and lenalidomide maintenance for untreated mantle cell lymphoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02633137. Published December 17, 2015. Accessed February 10, 2020."},{"key":"bibr30-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125004"},{"key":"bibr31-1060028020909117","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903518345"},{"key":"bibr32-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-523845"},{"key":"bibr33-1060028020909117","unstructured":"Dreyling M. ASCT after a rituximab\/ibrutinib\/Ara-c containing iNduction in generalized mantle cell lymphoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02858258. Published August 8, 2016. Accessed February 10, 2020."},{"key":"bibr34-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126920"},{"key":"bibr35-1060028020909117","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.167627"},{"key":"bibr36-1060028020909117","unstructured":"ECOG-ACRIN Cancer Research Group. Rituximab with or without stem cell transplant in treating patients with minimal residual disease-negative mantle cell lymphoma in first complete remission. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03267433. Published August 30, 2017. Accessed February 10, 2020."},{"key":"bibr37-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0079"},{"key":"bibr38-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"bibr39-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"bibr40-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00605"},{"key":"bibr41-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000526"},{"key":"bibr42-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30185-5"},{"key":"bibr43-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13929"},{"key":"bibr44-1060028020909117","unstructured":"Washington University School of Medicine. Bendamustine and rituximab alternating with cytarabine and rituximab for untreated mantle cell lymphoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02728531. Published April 5, 2016. Accessed February 10, 2020."},{"key":"bibr45-1060028020909117","unstructured":"Dana-Farber Cancer Institute. Rituximab\/bendamustine + rituximab\/cytarabine for mantle cell lymphoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01661881. Published August 10, 2012. Accessed February 10, 2020."},{"key":"bibr46-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110520"},{"key":"bibr47-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.7503"},{"key":"bibr48-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1002\/hon.75_2631"},{"key":"bibr49-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129404"},{"key":"bibr50-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2135-8"},{"key":"bibr51-1060028020909117","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1026818"},{"key":"bibr52-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.86"},{"key":"bibr53-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1666378"},{"key":"bibr54-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2350"},{"key":"bibr55-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24921"},{"key":"bibr56-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy458"},{"key":"bibr57-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3624"},{"key":"bibr58-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1996.00440020081010"},{"key":"bibr59-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505237"},{"key":"bibr60-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12172"},{"key":"bibr61-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12708"},{"key":"bibr62-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14866"},{"key":"bibr63-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70200-0"},{"key":"bibr64-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-859769"},{"key":"bibr65-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.162"},{"key":"bibr66-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127291"},{"key":"bibr67-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018016683"},{"key":"bibr68-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-017-0002-2"},{"key":"bibr69-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583302"},{"key":"bibr70-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-704023"},{"key":"bibr71-1060028020909117","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.154211"},{"key":"bibr72-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14669"},{"key":"bibr73-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1515465"},{"key":"bibr74-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1808-5"},{"key":"bibr75-1060028020909117","unstructured":"Velcade [package insert]. Cambridge, MA: Millenium Pharmaceuticals Inc; 2018. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=1521d321-e724-4ffc-adad-34bf4f44fac7. Accessed February 11, 2020."},{"key":"bibr76-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412096"},{"key":"bibr77-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30685-5"},{"key":"bibr78-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-271676"},{"key":"bibr79-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"bibr80-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1321750"},{"key":"bibr81-1060028020909117","unstructured":"SCRI Development Innovations, LLC. Rituximab, lenalidomide, and bortezomib in mantle cell lymphoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00633594. Published March 12, 2008. Accessed February 10, 2020."},{"key":"bibr82-1060028020909117","unstructured":"Alliance for Clinical Trials in Oncology. Bortezomib after combination chemotherapy, rituximab, and an autologous stem cell transplant in treating patients with mantle cell lymphoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00310037. Published April 3, 2006. Accessed February 10, 2020."},{"key":"bibr83-1060028020909117","unstructured":"City of Hope Medical Center. Bortezomib and rituximab in treating patients with mantle cell lymphoma who have previously undergone stem cell transplantation. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01267812. Published December 29, 2010. Accessed February 10, 2020."},{"key":"bibr84-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15107"},{"key":"bibr85-1060028020909117","unstructured":"PrECOG, LLC. A study of ixazomib and ibrutinib in relapsed\/refractory mantle cell lymphoma (PrE0404). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03323151. Published October 26, 2017. Accessed February 10, 2020."},{"key":"bibr86-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1429605"},{"key":"bibr87-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-2118"},{"key":"bibr88-1060028020909117","unstructured":"Imbruvica [package insert]. Sunnyvale, CA: Pharmacyclics LLC; 2018. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44. Accessed February 11, 2020."},{"key":"bibr89-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.121"},{"key":"bibr90-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125800"},{"key":"bibr91-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1965"},{"key":"bibr92-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-482125"},{"key":"bibr93-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126044"},{"key":"bibr94-1060028020909117","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10716"},{"key":"bibr95-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-257485"},{"key":"bibr96-1060028020909117","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.575489"},{"key":"bibr97-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16008"},{"key":"bibr98-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1002\/hon.51_2630"},{"key":"bibr99-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0010"},{"key":"bibr100-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"bibr101-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00667-4"},{"key":"bibr102-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0023-2"},{"key":"bibr103-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583294"},{"key":"bibr104-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.4471.4471"},{"key":"bibr105-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124691"},{"key":"bibr106-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1002\/hon.16_2629"},{"key":"bibr107-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125947"},{"key":"bibr108-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2503"},{"key":"bibr109-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1339874"},{"key":"bibr110-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix687"},{"key":"bibr111-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy175"},{"key":"bibr112-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1457147"},{"key":"bibr113-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2565"},{"key":"bibr114-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2018.01.004"},{"key":"bibr115-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3048"},{"key":"bibr116-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.4320"},{"key":"bibr117-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257"},{"key":"bibr118-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05094.x"},{"key":"bibr119-1060028020909117","unstructured":"University of Michigan Rogel Cancer Center. Venetoclax, lenalidomide and rituximab in patients with previously untreated mantle cell lymphoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03523975. Published May 14, 2018. Accessed February 10, 2020."},{"key":"bibr120-1060028020909117","unstructured":"Memorial Sloan Kettering Cancer Center. The study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03295240. Published September 27, 2017. Accessed February 10, 2020."},{"key":"bibr121-1060028020909117","unstructured":"Nantes University Hospital. A trial of obinutuzumab, GDC-0199 plus ibrutinib in relapsed\/refractory mantle cell lymphoma patients (OAsIs). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02558816. Published September 24, 2015. Accessed February 10, 2020."},{"key":"bibr122-1060028020909117","unstructured":"M D Anderson Cancer Center. Ibrutinib, rituximab, venetoclax, and combination chemotherapy in treating patients with newly diagnosed mantle cell lymphoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03710772. Published October 18, 2018. Accessed February 10, 2020."},{"key":"bibr123-1060028020909117","unstructured":"Fondazione Italiana Linfomi ONLUS. Rituximab, bendamustine and cytarabine followed by venetoclax in high risk elderly patients with MCL. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03567876. Published June 26, 2018. Accessed February 10, 2020."},{"key":"bibr124-1060028020909117","unstructured":"Acerta Pharma BV. A study of acalabrutinib in combination with rituximab + (bendamustine or venetoclax) in subjects with MCL. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02717624. Published March 24, 2016. Accessed February 10, 2020."},{"key":"bibr125-1060028020909117","unstructured":"Nordic Lymphoma Group.Venetoclax, lenalidomide and rituximab in patients with relapsed\/refractory mantle cell lymphoma (VALERIA). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03505944. Published April 23, 2018. Accessed February 10, 2020."},{"key":"bibr126-1060028020909117","unstructured":"PrECOG, LLC. Phase II study of bendamustine and rituximab plus venetoclax in untreated mantle cell lymphoma over 60 years of age (PrE0405). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03834688. Published February 8, 2019. Accessed February 10, 2020."},{"key":"bibr127-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1002\/hon.146_2630"},{"key":"bibr128-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-125681"},{"key":"bibr129-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.708.708"},{"key":"bibr130-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13149"},{"key":"bibr131-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.249"},{"key":"bibr132-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.155"},{"key":"bibr133-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126619"},{"key":"bibr134-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715519"},{"key":"bibr135-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00438-6"},{"key":"bibr136-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30018-8"},{"key":"bibr137-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-388298"},{"key":"bibr138-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1612062"},{"key":"bibr139-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-886457"},{"key":"bibr140-1060028020909117","unstructured":"Alliance Foundation Trials, LLC. Phase II palbociclib +ibrutinib in mantle cell lymphoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03478514. Published March 27, 2018. Accessed February 10, 2020."},{"key":"bibr141-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1421"},{"key":"bibr142-1060028020909117","unstructured":"Swiss Group for Clinical Cancer Research. Combination of ibrutinib and bortezomib to treat patients with mantle cell lymphoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02356458. Published February 5, 2015. Accessed February 10, 2020."},{"key":"bibr143-1060028020909117","unstructured":"Calquence [package insert]. Gaithersburg, MD: AstraZeneca Pharmaceuticals LP; 2017. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=dd4835ef-e1bc-4997-a399-1ffa2556fbfe. Accessed February 11, 2020."},{"key":"bibr144-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.2920.2920"},{"key":"bibr145-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.2908.2908"},{"key":"bibr146-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0575-9"},{"key":"bibr147-1060028020909117","first-page":"4326","volume":"130","author":"Byrd JC","year":"2017","journal-title":"Blood"},{"key":"bibr148-1060028020909117","first-page":"1741","volume":"130","author":"Covey T","year":"2017","journal-title":"Blood"},{"key":"bibr149-1060028020909117","unstructured":"Washington University School of Medicine. Acalabrutinib with alternating cycles of bendamustine\/rituximab and cytarabine\/rituximab for untreated mantle cell lymphoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03623373. Published August 9, 2018. Accessed February 10, 2020."},{"key":"bibr150-1060028020909117","unstructured":"Acerta Pharma BV. A Study of bendamustine and rituximab alone versus in combination with acalabrutinib in subjects with previously untreated mantle cell lymphoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02972840. Published November 25, 2016. Accessed February 10, 2020."},{"key":"bibr151-1060028020909117","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.220590"},{"key":"bibr152-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1002\/hon.15_2629"},{"key":"bibr153-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1002\/hon.55_2630"},{"key":"bibr154-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129829"},{"key":"bibr155-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-737502"},{"key":"bibr156-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126305"},{"key":"bibr157-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-664086"},{"key":"bibr158-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0658-7"},{"key":"bibr159-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.5393.5393"},{"key":"bibr160-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25418"},{"key":"bibr161-1060028020909117","unstructured":"Yescarta [package insert]. Los Angeles, CA: Kite Pharma Inc; 2017. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=9b70606e-b99c-4272-a0f1-b5523cce0c59. Accessed February 11, 2020."},{"key":"bibr162-1060028020909117","unstructured":"Kite, A Gilead Company. A phase 2 multicenter study evaluating subjects with relapsed\/refractory mantle cell lymphoma (ZUMA-2). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02601313. Published November 10, 2015. Accessed February 10, 2020."},{"key":"bibr163-1060028020909117","unstructured":"Hackensack Meridian Health. John Theurer Cancer Center part of multi-center study with National Cancer Institute and Kita Pharma for CAR-T cell therapy study showing very impressive results in aggressive lymphoma refractory to chemotherapy. CISION. PR Newswire. https:\/\/www.prnewswire.com\/news-releases\/john-theurer-cancer-center-part-of-multi-center-study-with-national-cancer-institute-and-kite-pharma-for-car-t-cell-therapy-study-showing-very-impressive-results-in-aggressive-lymphoma-refractory-to-chemotherapy-300418355.html. Published May 6, 2017. Accessed February 10, 2020."},{"key":"bibr164-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7516"},{"key":"bibr165-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129666"},{"key":"bibr166-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"bibr167-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1248965"},{"key":"bibr168-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0098"},{"key":"bibr169-1060028020909117","unstructured":"Incyte Corporation. A study of INCB050465 in relapsed or refractory mantle cell lymphoma previously treated with or without a BTK inhibitor (CITADEL-205). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03235544. Published August 1, 2017. Accessed February 10, 2020."},{"key":"bibr170-1060028020909117","unstructured":"Memorial Sloan Kettering Cancer Center. A clinical trial of buparlisib and ibrutinib in lymphoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02756247. Published April 29, 2016. Accessed February 10, 2020."},{"key":"bibr171-1060028020909117","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2017.01.001"},{"key":"bibr172-1060028020909117","unstructured":"University of Washington. Enzalutamide in treating patients with relapsed or refractory mantle cell lymphoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02489123. Published July 2, 2015. Accessed February 10, 2020."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020909117","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028020909117","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028020909117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:27Z","timestamp":1777374927000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028020909117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":172,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1177\/1060028020909117"],"URL":"https:\/\/doi.org\/10.1177\/1060028020909117","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,20]]}}}